713 related articles for article (PubMed ID: 29896193)
21. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
Diebold M; Sievers C; Bantug G; Sanderson N; Kappos L; Kuhle J; Lindberg RLP; Derfuss T
J Autoimmun; 2018 Jan; 86():39-50. PubMed ID: 28958667
[TBL] [Abstract][Full Text] [Related]
22. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.
Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS
Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
24. Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment.
Walo-Delgado PE; Sainz de la Maza S; Villarrubia N; Monreal E; Medina S; Espiño M; Fernández-Velasco JI; Rodríguez-Martín E; Roldán E; Lourido D; Muriel A; Masjuan-Vallejo J; Costa-Frossard L; Villar LM
Sci Rep; 2021 Apr; 11(1):9299. PubMed ID: 33927255
[TBL] [Abstract][Full Text] [Related]
25. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
Front Immunol; 2019; 10():1666. PubMed ID: 31379857
[No Abstract] [Full Text] [Related]
26. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
[TBL] [Abstract][Full Text] [Related]
27. Circulating follicular T helper cells and humoral reactivity in rheumatic heart disease.
Liu Z; Wang Y; Li F; Xie F; Liu M; Shi J; Dong N
Life Sci; 2020 Mar; 245():117390. PubMed ID: 32007574
[TBL] [Abstract][Full Text] [Related]
28. Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris.
Wang Y; Wang L; Shi Y; Wang F; Yang H; Han S; Bai Y
Immunol Lett; 2017 Jan; 181():101-108. PubMed ID: 27662792
[TBL] [Abstract][Full Text] [Related]
29. Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
Puthenparampil M; Zito A; Pantano G; Federle L; Stropparo E; Miante S; De Silvestro G; Plebani M; Gallo P
Mult Scler; 2019 Jun; 25(7):918-926. PubMed ID: 29882478
[TBL] [Abstract][Full Text] [Related]
30. Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease.
Chen Y; Lin W; Yang H; Wang M; Zhang P; Feng R; Chen H; Peng L; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W; Lipsky PE
Arthritis Rheumatol; 2018 Nov; 70(11):1853-1865. PubMed ID: 29781221
[TBL] [Abstract][Full Text] [Related]
31. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
[TBL] [Abstract][Full Text] [Related]
32. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.
Medina S; Villarrubia N; Sainz de la Maza S; Lifante J; Costa-Frossard L; Roldán E; Picón C; Álvarez-Cermeño JC; Villar LM
Mult Scler; 2018 Sep; 24(10):1317-1327. PubMed ID: 28653862
[TBL] [Abstract][Full Text] [Related]
33. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
35. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
36. Integrating circulating T follicular memory cells and autoantibody repertoires for characterization of autoimmune disorders.
Harris EM; Chamseddine S; Chu A; Senkpeil L; Nikiciuk M; Al-Musa A; Woods B; Ozdogan E; Saker S; van Konijnenburg DPH; Yee CSK; Nelson R; Lee P; Halyabar O; Hale RC; Day-Lewis M; Henderson LA; Nguyen AA; Elkins M; Ohsumi TK; Gutierrez-Arcelus M; Peyper JM; Platt CD; Grace RF; LaBere B; Chou J
medRxiv; 2024 Mar; ():. PubMed ID: 38464255
[TBL] [Abstract][Full Text] [Related]
37. Dimethyl fumarate treatment in relapsing remitting MS changes the inflammatory CSF protein profile by a prominent decrease in T-helper 1 immunity.
Hojjati S; Ernerudh J; Vrethem M; Mellergård J; Raffetseder J
Mult Scler Relat Disord; 2023 Dec; 80():105126. PubMed ID: 37952502
[TBL] [Abstract][Full Text] [Related]
38. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An
Dobreanu M; Manu DR; Mănescu IB; Gabor MR; Huţanu A; Bărcuţean L; Bălaşa R
Front Immunol; 2021; 12():743010. PubMed ID: 34970256
[TBL] [Abstract][Full Text] [Related]
39. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
40. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
